Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease

Trends in Neurosciences

Volumn 31, Issue 9, 2008, Pages 454-463

  Bezprozvanny, Ilya ^a   Mattson, Mark P ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; ANTIINFLAMMATORY AGENT; BETA SECRETASE INHIBITOR; BRAIN DERIVED NEUROTROPHIC FACTOR; CALCIUM ION; EPHRIN RECEPTOR B2; FOLIC ACID; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; HYDROGEN PEROXIDE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NOTCH RECEPTOR; OMEGA 3 FATTY ACID; PLANT MEDICINAL PRODUCT; PRESENILIN 1; PRESENILIN 2;

AGING; ALZHEIMER DISEASE; APOPTOSIS; BRAIN NERVE CELL; CALCIUM CELL LEVEL; CALCIUM HOMEOSTASIS; CALCIUM MOBILIZATION; CALCIUM SIGNALING; CALCIUM TRANSPORT; CALORIC RESTRICTION; CELL MEMBRANE; CHOLINERGIC TRANSMISSION; COGNITIVE DEFECT; CYTOSKELETON; ELECTROPHYSIOLOGY; ENDOPLASMIC RETICULUM; ENVIRONMENTAL ENRICHMENT; EXCITOTOXICITY; EXERCISE; GENE MUTATION; HUMAN; IMMUNIZATION; LIPID PEROXIDATION; MEMBRANE CONDUCTANCE; NERVE CELL EXCITABILITY; NERVE CELL MEMBRANE; NERVE CELL NECROSIS; NERVE FIBER; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; OLIGOMERIZATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SYNAPSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; CALCIUM; CALCIUM SIGNALING; HUMANS; NEURONS; PRESENILINS; SIGNAL TRANSDUCTION; SYNAPSES;

EID: 50249135503     PISSN: 01662236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tins.2008.06.005     Document Type: Review

References (89)

1. Berridge M.J., et al. Calcium-a life and death signal. Nature 395 (1998) 645-648
2. Spät A., et al. High- and low-calcium-dependent mechanisms of mitochondrial calcium signalling. Cell Calcium 44 (2008) 51-63
3. Hardy J. A hundred years of Alzheimer's disease research. Neuron 52 (2006) 3-13
4. Mattson M.P., and Magnus T. Ageing and neuronal vulnerability. Nat. Rev. Neurosci. 7 (2006) 278-294
5. Murchison D., and Griffith W.H. Calcium buffering systems and calcium signaling in aged rat basal forebrain neurons. Aging Cell 6 (2007) 297-305
6. Brown M.R., et al. Brain region-specific, age-related, alterations in mitochondrial responses to elevated calcium. J. Bioenerg. Biomembr. 36 (2004) 401-406
7. 2+ regulation and gene expression in normal brain aging. Trends Neurosci. 27 (2004) 614-620
8. Poon H.F., et al. Proteomics analysis provides insight into caloric restriction mediated oxidation and expression of brain proteins associated with age-related impaired cellular processes: mitochondrial dysfunction, glutamate dysregulation and impaired protein synthesis. Neurobiol. Aging 27 (2006) 1020-1034
9. Blalock E.M., et al. Gene microarrays in hippocampal aging: statistical profiling identifies novel processes correlated with cognitive impairment. J. Neurosci. 23 (2003) 3807-3819
10. Emilsson L., et al. Alzheimer's disease: mRNA expression profiles of multiple patients show alterations of genes involved with calcium signaling. Neurobiol. Dis. 21 (2006) 618-625
11. Mattson M.P. Pathways towards and away from Alzheimer's disease. Nature 430 (2004) 631-639
12. Haass C., and Selkoe D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide. Nat. Rev. Mol. Cell Biol. 8 (2007) 101-112
13. Mattson M.P., et al. β-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J. Neurosci. 12 (1992) 376-389
14. Demuro A., et al. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J. Biol. Chem. 280 (2005) 17294-17300
15. Meyer-Luehmann M., et al. Rapid appearance and local toxicity of amyloid-β plaques in a mouse model of Alzheimer's disease. Nature 451 (2008) 720-724
16. + channels and suppression of neuronal activity by secreted β-amyloid-precursor protein. Nature 379 (1996) 74-78
17. Leissring M.A., et al. A physiologic signaling role for the γ-secretase-derived intracellular fragment of APP. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 4697-4702
18. Arispe N., et al. Alzheimer disease amyloid β protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 567-571
19. Yoshiike Y., et al. Pore-forming proteins share structural and functional homology with amyloid oligomers. Neuromolecular Med. 9 (2007) 270-275
20. Lee G., et al. Annexin 5 and apolipoprotein E2 protect against Alzheimer's amyloid-β-peptide cytotoxicity by competitive inhibition at a common phosphatidylserine interaction site. Peptides 23 (2002) 1249-1263
21. Simakova O., and Arispe N.J. The cell-selective neurotoxicity of the Alzheimer's Aβ peptide is determined by surface phosphatidylserine and cytosolic ATP levels. Membrane binding is required for Aβ toxicity. J. Neurosci. 27 (2007) 13719-13729
22. Sahu S.K., et al. Phospholipid scramblases: an overview. Arch. Biochem. Biophys. 462 (2007) 103-114
23. Hensley K., et al. A model for β-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 3270-3274
24. Huang X., et al. The A β peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 38 (1999) 7609-7616
25. Mark R.J., et al. Amyloid β-peptide impairs glucose transport in hippocampal and cortical neurons: involvement of membrane lipid peroxidation. J. Neurosci. 17 (1997) 1046-1054
26. Shankar G.M., et al. Natural oligomers of the Alzheimer amyloid-β protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J. Neurosci. 27 (2007) 2866-2875
27. Nimmrich V., et al. Amyloid β oligomers (A β (1-42) globulomer) suppress spontaneous synaptic activity by inhibition of P/Q-type calcium currents. J. Neurosci. 28 (2008) 788-797
28. Liu Q., et al. β-Amyloid peptide blocks the response of α 7-containing nicotinic receptors on hippocampal neurons. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 4734-4749
29. Dougherty J.J., et al. β-Amyloid regulation of presynaptic nicotinic receptors in rat hippocampus and neocortex. J. Neurosci. 23 (2003) 6740-6747
30. Baker N.E. Notch signaling in the nervous system. Pieces still missing from the puzzle. Bioessays 22 (2000) 264-273
31. Wang Y., et al. Involvement of Notch signaling in hippocampal synaptic plasticity. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 9458-9462
32. 2+ mobilization is altered in fibroblasts from patients with Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 534-538
33. Guo Q., et al. Alzheimer's PS-1 mutation perturbs calcium homeostasis and sensitizes PC12 cells to death induced by amyloid β-peptide. Neuroreport 8 (1996) 379-383
34. Guo Q., et al. Alzheimer's presenilin mutation sensitizes neural cells to apoptosis induced by trophic factor withdrawal and amyloid β-peptide: involvement of calcium and oxyradicals. J. Neurosci. 17 (1997) 4212-4222
35. Leissring M.A., et al. Alzheimer's presenilin-1 mutation potentiates inositol 1,4,5-trisphosphate-mediated calcium signaling in Xenopus oocytes. J. Neurochem. 72 (1999) 1061-1068
36. Guo Q. Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice. Nat. Med. 5 (1999) 101-106
37. 2+ signals and altered membrane excitability. J. Neurosci. 24 (2004) 508-513
38. Schneider I., et al. Mutant presenilins disturb neuronal calcium homeostasis in the brain of transgenic mice, decreasing the threshold for excitotoxicity and facilitating long-term potentiation. J. Biol. Chem. 276 (2001) 11539-11544
39. Begley J.G., et al. Altered calcium homeostasis and mitochondrial dysfunction in cortical synaptic compartments of presenilin-1 mutant mice. J. Neurochem. 72 (1999) 1030-1039
40. Chan S.L., et al. Presenilin-1 mutations increase levels of ryanodine receptors and calcium release in PC12 cells and cortical neurons. J. Biol. Chem. 275 (2000) 18195-18200
41. Pack-Chung E., et al. Presenilin 2 interacts with sorcin, a modulator of the ryanodine receptor. J. Biol. Chem. 275 (2000) 14440-14445
42. Stabler S.M., et al. A myristoylated calcium-binding protein that preferentially interacts with the Alzheimer's disease presenilin 2 protein. J. Cell Biol. 145 (1999) 1277-1292
43. Buxbaum J.D., et al. Calsenilin: a calcium-binding protein that interacts with the presenilins and regulates the levels of a presenilin fragment. Nat. Med. 4 (1998) 1177-1181
44. Green K.N., et al. SERCA pump activity is physiologically regulated by presenilin and regulates amyloid β production. J. Cell Biol. 181 (2008) 1107-1116
45. 2+ homeostasis and accelerates apoptosis. J. Biol. Chem. 281 (2006) 16649-16655
46. 3 receptor channel gating. Neuron 58 (2008) 871-883
47. 2+ disruptions in young, adult, and aged Alzheimer's disease mice. J. Neurosci. 26 (2006) 5180-5189
48. 2+ leak channels, a function disrupted by familial Alzheimer's disease-linked mutations. Cell 126 (2006) 981-993
49. 2+ leak function of presenilin 1. J. Clin. Invest. 117 (2007) 1230-1239
50. Cedazo-Minguez A., et al. The presenilin 1 δE9 mutation gives enhanced basal phospholipase C activity and a resultant increase in intracellular calcium concentrations. J. Biol. Chem. 277 (2002) 36646-36655
51. Dumanchin C., et al. Biological effects of four PSEN1 gene mutations causing Alzheimer disease with spastic paraparesis and cotton wool plaques. Hum. Mutat. 27 (2006) 1063
52. McKee A.C., et al. Hippocampal neurons predisposed to neurofibrillary tangle formation are enriched in type II calcium/calmodulin-dependent protein kinase. J. Neuropathol. Exp. Neurol. 49 (1990) 49-63
53. Nixon R.A. The calpains in aging and aging-related diseases. Ageing Res. Rev. 2 (2003) 407-418
54. Botella-Lopez A., et al. Reelin expression and glycosylation patterns are altered in Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 5573-5578
55. 2+ influx in cultured hippocampal neurons. Neuron 4 (1990) 105-117
56. Furukawa K., et al. Alteration in calcium channel properties is responsible for the neurotoxic action of a familial frontotemporal dementia tau mutation. J. Neurochem. 87 (2003) 427-436
57. Querfurth H.W., and Selkoe D.J. Calcium ionophore increases amyloid β peptide production by cultured cells. Biochemistry 33 (1994) 4550-4561
58. Zhang X., et al. Hypoxia-inducible factor 1α (HIF-1α)-mediated hypoxia increases BACE1 expression and β-amyloid generation. J. Biol. Chem. 282 (2007) 10873-10880
59. Buxbaum J.D., et al. Calcium regulates processing of the Alzheimer amyloid protein precursor in a protein kinase C-independent manner. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 4489-4493
60. Petryniak M.A., et al. Elevated intracellular calcium concentration increases secretory processing of the amyloid precursor protein by a tyrosine phosphorylation-dependent mechanism. Biochem. J. 320 (1996) 957-963
61. Lazarov O., et al. Evidence that synaptically released β-amyloid accumulates as extracellular deposits in the hippocampus of transgenic mice. J. Neurosci. 22 (2002) 9785-9793
62. Spires-Jones T.L., et al. Impaired spine stability underlies plaque-related spine loss in an Alzheimer's disease mouse model. Am. J. Pathol. 171 (2007) 1304-1311
63. Celsi F., et al. β-Amyloid causes downregulation of calcineurin in neurons through induction of oxidative stress. Neurobiol. Dis. 26 (2007) 342-352
64. Lacor P.N., et al. Aβ oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J. Neurosci. 27 (2007) 796-807
65. Janus C., et al. A β peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408 (2000) 979-982
66. Palop J.J. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 55 (2007) 697-711
67. Priller C., et al. Mutant presenilin 1 alters synaptic transmission in cultured hippocampal neurons. J. Biol. Chem. 282 (2007) 1119-1127
68. Shemer I., et al. Non-fibrillar β-amyloid abates spike-timing-dependent synaptic potentiation at excitatory synapses in layer 2/3 of the neocortex by targeting postsynaptic AMPA receptors. Eur. J. Neurosci. 23 (2006) 2035-2047
69. Haughey N.J., et al. Disruption of neurogenesis by amyloid β-peptide, and perturbed neural progenitor cell homeostasis, in models of Alzheimer's disease. J. Neurochem. 83 (2002) 1509-1524
70. Huang Y. Apolipoprotein E and Alzheimer disease. Neurology 66 (2006) S79-S85
71. Hartmann H., et al. Apolipoprotein E and cholesterol affect neuronal calcium signalling: the possible relationship to β-amyloid neurotoxicity. Biochem. Biophys. Res. Commun. 200 (1994) 1185-1192
72. Chen Y., et al. Reelin modulates NMDA receptor activity in cortical neurons. J. Neurosci. 25 (2005) 8209-8216
73. Chin J., et al. Reelin depletion in the entorhinal cortex of human amyloid precursor protein transgenic mice and humans with Alzheimer's disease. J. Neurosci. 27 (2007) 2727-2733
74. Iritani S., et al. Relationship of calbindin D28K-immunoreactive cells and neuropathological changes in the hippocampal formation of Alzheimer's disease. Neuropathology 21 (2001) 162-167
75. Geula C., et al. Loss of calbindin-D28k from aging human cholinergic basal forebrain: relation to neuronal loss. J. Comp. Neurol. 455 (2003) 249-259
76. Mikkonen M., et al. Subfield- and layer-specific changes in parvalbumin, calretinin and calbindin-D28K immunoreactivity in the entorhinal cortex in Alzheimer's disease. Neuroscience 92 (1999) 515-532
77. Mishizen-Eberz A.J., et al. Biochemical and molecular studies of NMDA receptor subunits NR1/2A/2B in hippocampal subregions throughout progression of Alzheimer's disease pathology. Neurobiol. Dis. 15 (2004) 80-92
78. Lazarov O., et al. Environmental enrichment reduces Aβ levels and amyloid deposition in transgenic mice. Cell 120 (2005) 701-713
79. Wolf S.A., et al. Cognitive and physical activity differently modulate disease progression in the amyloid precursor protein (APP)-23 model of Alzheimer's disease. Biol. Psychiatry 60 (2006) 1314-1323
80. Halagappa V.K., et al. Intermittent fasting and caloric restriction ameliorate age-related behavioral deficits in the triple-transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. 26 (2007) 212-220
81. Mattson M.P., et al. BDNF and 5-HT: a dynamic duo in age-related neuronal plasticity and neurodegenerative disorders. Trends Neurosci. 27 (2004) 589-594
82. Schmidt B., et al. Inhibitors and modulators of β- and γ-secretase. Curr. Top. Med. Chem. 6 (2006) 377-392
83. Lipton S.A. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat. Rev. Drug Discov. 5 (2006) 160-170
84. Bachurin S., et al. Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer. Ann. N. Y. Acad. Sci. 939 (2001) 425-435
85. Grigorev V.V., et al. Comparative study of action mechanisms of dimebon and memantine on AMPA- and NMDA-subtypes glutamate receptors in rat cerebral neurons. Bull. Exp. Biol. Med. 136 (2003) 474-477
86. Lindholm D., et al. ER stress and neurodegenerative diseases. Cell Death Differ. 13 (2006) 385-392
87. 2+ homeostasis and mitochondrial function during endoplasmic reticulum stress. J. Biol. Chem. 279 (2004) 28733-28743
88. +2 exchange are reduced in Alzheimer's disease cybrids. Mitochondrion 5 (2005) 109-119
89. Chan S.L., et al. Mitochondrial uncoupling protein-4 regulates calcium homeostasis and sensitivity to store depletion-induced apoptosis in neural cells. J. Biol. Chem. 281 (2006) 37391-37403